TIGATX INC

Biotech · Private

IgA-based monoclonal antibody (TIGA-001) for EGFR-mutant non-small cell lung cancer

Grants
$1.4M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers$1,418,424
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2982NuPeak Therapeutics, Inc.——
2983SINGULAR IMMUNE, INC.——
2984GLOW THERAPEUTICS INC.——
2985TIGATX INC——
2986Whisper Biosciences——
2987Singular Genomics——
2988SYNTIRON, LLC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Engineered Iga Antibodies And Methods Of Useapplication
  • Engineered Iga Antibodies And Methods Of Useapplication
  • Engineered Iga Antibodies And Methods Of Useapplication
  • Indinavir Based Chemical Dimerization T Cell Engager Compositionsapplication
  • Compositions And Methods Of ANTI-CD47 Bispecific Antibodiesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.